SCHEDULE: BBRC Urges Vote Against Victoria's Secret Directors
Proxy Contest Announcement
Activist investor BBRC is soliciting votes against two Victoria's Secret directors, citing underperformance and governance concerns.
Summary
- BBRC International PTE Limited, a significant stockholder holding approximately 13% of Victoria's Secret & Co. (VSCO), has filed a preliminary proxy statement to solicit votes against the reelection of two directors: Chair Donna James and Director Mariam Naficy, at the 2026 Annual Meeting.
- BBRC cites underperformance of VSCO shares compared to the S&P 500 Consumer Discretionary Distribution & Retail Index by approximately 92 percentage points during their investment period.
- The firm alleges ineffective Board oversight led to misallocation of $1.2 billion in capital for poorly executed buybacks and acquisitions, specifically mentioning the $591 million Adore Me acquisition which resulted in $155 million in impairments and charges with no demonstrable synergies or accretion.
- Concerns are raised about excessive director tenure, particularly Ms. James' 25-year tenure, and a lack of Board alignment with shareholders due to limited personal financial exposure to the company's stock.
- BBRC also points to a significant decline in net income (75.1%) and operating margins, as well as a failure to meet fiscal year 2026 guidance targets set at the 2023 Investor Day.
- Governance issues highlighted include the adoption of a 'poison pill' without stockholder approval and a lack of responsiveness to stockholder concerns, such as a significant dissent on executive compensation at the 2025 Annual Meeting.
Sentiment
Score: 2
Explanation: StockSavvy.ai views this as a strongly negative filing due to the direct challenge to board members, detailed financial underperformance, and significant governance criticisms.
Positives
- Victoria's Secret & Co. has initiated a turnaround effort under new leadership.
- The company has replaced its CEO and CFO in recent years, incurring $13 million in severance and related expenses.
- BBRC acknowledges the potential of the business and invested in VS four years ago based on this belief.
Negatives
- VSCO shares have underperformed the S&P 500 Consumer Discretionary Distribution & Retail Index by approximately 92 percentage points since BBRC's investment.
- Net income fell from $646 million to $161 million (a 75.1% decline) between fiscal year 2021 and fiscal year 2025.
- Diluted EPS fell from $7.18 to $1.93 during the same period.
- Operating margins collapsed from 12.8% to 4.1%.
- The $591 million Adore Me acquisition has resulted in over $155 million in impairments and restructuring charges with no meaningful synergies or accretion.
- Share repurchases totaling $625 million generated a negligible $0.28 per share of EPS improvement.
- Fiscal year 2026 revenue guidance of $6.85-$6.95 billion falls short of the $7.4 billion target, and operating margin guidance of approximately 6.5% is significantly below the 10%-12% target range.
Risks
- Continued underperformance due to ineffective Board oversight and capital allocation decisions.
- Failure to achieve turnaround goals and meet future financial targets.
- Potential for further value destruction if governance issues are not addressed.
- The Adore Me acquisition's ongoing lack of strategic purpose and financial contribution.
- The risk that the Board's limited stock ownership may lead to prioritizing self-preservation over shareholder value.
Future Outlook
The filing does not provide forward-looking statements from Victoria's Secret & Co. itself, but BBRC's campaign is aimed at improving future governance and oversight to accelerate the company's turnaround.
Management Comments
- BBRC invested in VS four years ago, after the Company separated from L Brands, Inc. (L Brands), based on our belief in the long-term potential of the business.
- We are concerned that the Boards interests are not aligned with shareholders because of its limited financial exposure to the decisions it makes.
- We believe this underperformance has been driven by the Boards ineffective oversight of management, which led to the misallocation of $1.2 billion for poorly executed buybacks and M&A with little demonstrable return.
- Excessive director tenure is incompatible with good governance... the specific consequence of excessive tenure that governance experts warn about has already occurred at VS: lacking the independence to challenge management and the fortitude to make hard decisions, the Board waited too long to transition away from the prior CEO it appointed.
- Stockholders deserve accountability from both Ms. James as Chair and Ms. Naficy as the director the Company's own proxy described as a key partner in overseeing that acquisition.
- These failures - a $591 million acquisition gone wrong, $625 million in poorly timed buybacks, a poison pill adopted without stockholder approval and the refusal to add a stockholder representative to the Board - will not be fixed by the directors who presided over them.
- Voting AGAINST Ms. James and Ms. Naficys reelection is akin to addition by subtraction - we believe that a Board without them will bring fresh judgment to capital allocation, free management to focus on the core business rather than optimizing a failed acquisition and attract directors with the expertise this next phase demands.
Industry Context
StockSavvy.ai notes that activist campaigns targeting director reelections are becoming more common as investors seek greater accountability for capital allocation and strategic execution, especially in the retail sector which has faced significant headwinds and transformation.
Comparison to Industry Standards
- Director tenure: BBRC highlights that over 75% of S&P 500 companies with tenure limits cap them at 15 years or less, and the National Association of Corporate Directors recommends a 10-year limit. Ms. James' 25-year tenure significantly exceeds these benchmarks.
- Shareholder alignment: The filing contrasts the Board's minimal stock ownership (<1% for non-executive directors) with BBRC's 13% stake, suggesting a misalignment of interests compared to typical institutional investor holdings.
- Capital allocation: The criticism of the Adore Me acquisition and buyback execution suggests a deviation from best practices in M&A and capital return strategies observed in more successful retail companies.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| CEO | Unknown | Unknown | 2024 | Poor succession decisions, failed strategic initiatives, and ineffective capital allocation. |
| CFO | Unknown | Unknown | 2024 | Poor succession decisions, failed strategic initiatives, and ineffective capital allocation. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Tenure | Criticism of Chair Donna James' 25-year tenure, exceeding recommended limits and potentially impacting independence. | Ongoing | Potential for weakened objectivity and delayed decision-making. |
| Stockholder Rights Plan (Poison Pill) | Adoption of a restrictive poison pill on May 20, 2025, without prior stockholder vote. | 2025-05-20 | Seen as an entrenchment tactic, limiting shareholder influence. |
| Board Composition | Failure to add a stockholder representative to the Board despite repeated calls from BBRC. | Ongoing | Perceived lack of responsiveness to shareholder concerns and limited independent oversight. |
| Director Stock Ownership | Low stock ownership by independent directors relative to their compensation ($0.15 million invested vs. $10.6 million compensation). | Ongoing | Suggests a potential prioritization of director fees over shareholder value. |
Legal Proceedings
- Donna James was named as a defendant in litigation (Rudi v. Wexner, et al., Case No. 2:20-cv-3068) that resulted in $90 million in governance reforms, including changes to the Audit Committee she led.
Stakeholder Impact
- Shareholders: Directly impacted by stock underperformance, potential value destruction, and the outcome of the proxy contest. BBRC aims to improve governance for their benefit.
- Employees: Potential impact on morale and strategic direction depending on the outcome of the board changes and turnaround efforts.
- Management: Faces increased scrutiny and pressure to improve performance and strategic execution.
- Creditors: Indirectly impacted by the company's financial health and ability to meet obligations.
Next Steps
- BBRC will solicit votes against the reelection of Donna James and Mariam Naficy at the 2026 Annual Meeting of Stockholders.
- BBRC expects to mail its definitive proxy statement and accompanying GOLD proxy card to stockholders.
- Stockholders are urged to vote using BBRC's Gold Proxy Card.
Key Dates
| Date | Description |
|---|---|
| 2021-08-01 | Separation from L Brands, Inc. |
| 2024-01-31 | End of fiscal year 2025 for Victoria's Secret & Co. |
| 2025-05-20 | Victoria's Secret & Co. Board adopted a poison pill. |
| 2025-11-04 | Victoria's Secret & Co. Board issued a press release regarding CEO replacement. |
| 2026-01-31 | End of fiscal year 2026 for Victoria's Secret & Co. |
| 2026-05-01 | Victoria's Secret & Co. filed its Proxy Statement on Schedule 14A. |
| 2026-05-04 | BBRC filed a preliminary proxy statement and issued an open letter to stockholders. |
| 2026-05-04 | Date of the press release and the filing of Amendment No. 5 to Schedule 13D. |
Recommendation
holdWhile BBRC's campaign highlights significant issues and a need for governance improvement, the current turnaround efforts and the outcome of the director elections introduce uncertainty. A 'hold' recommendation allows investors to await the results of the annual meeting and observe the impact of any board changes on the company's strategic direction and financial performance before making a more definitive decision.
Keywords
Victoria's Secret, VSCO, BBRC, Director Election, Corporate Governance, Activist Investor, Shareholder Vote, Adore Me Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.